Remission of uterine leiomyosarcomas treated with vincristine, Adriamycin, and dimethyl-triazeno-imidazole carboximide.
Six patients with metastatic uterine leiomyosarcoma have been treated with the combination of vincristine, Adriamycin, and DTIC. Complete remissions were obtained in three patients and a partial remission in a fourth. The average duration of response was 15.6 months and one patient is free of disease at 24 months. Severe nausea and vomiting caused discontinuance of chemotherapy in two patients.
D000328:Adult; D000368:Aged; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous; D014226:Triazenes / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D014226:Triazenes; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin